Rinsho Shinkeigaku (Clinical Neurology)

Brief Clinical Note

Analysis of PEG-J associated complications in 14 adult patients treated with levodopa-carbidopa intestinal gel

Munehisa Shimamura, M.D., Ph.D.1), Shinichiro Shinzaki, M.D., Ph.D.2), Kensuke Ikenaka, M.D., Ph.D.1), Kuni Konaka, M.D., Ph.D.1), Daisuke Hirozawa, M.D.1), Teruyuki Ishikura, M.D.1), Makoto Hideshima, M.D.1), Tomohito Nakano, M.D.1), Takaya Kitano, M.D., Ph.D.1), Tetsuo Takehara, M.D., Ph.D.2) and Hideki Mochizuki, M.D., Ph.D.1)

1)Department of Neurology, Graduate School of Medicine, Osaka University
2)Department of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University

We analyzed 14 patients in our hospital, who underwent levodopa-carbidopa intestinal gel (LCIG) treatment through a percutaneous endoscopic gastrojejunostomy (PEG-J). The PEG-J related complications were observed in 10 patients (71.4%). Detailed complications are as followings: J-tube related complications such as kinking (3 cases, 21.4%), pump malfunctions (3 cases, 21.4%), skin troubles in the gastrostoma (7 cases, 50.0%), duodenal perforation, peritonitis, and ulcers (2 cases, 14.3%). These results indicated that the sufficient care for PEG-J associated complications are important in LCIG treatment.
Full Text of this Article in Japanese PDF (284K)

(CLINICA NEUROL, 59: 153|156, 2019)
key words: Parkinson's disease, levodopa-carbidopa intestinal gel treatment, percutaneous endoscopic gastrojejunostomy, complications

(Received: 21-Jun-18)